Journal Article

FZJ-2017-00705

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Galldiks, N. (Corresponding author)FZJ* ; Law, I. ; Pope, W. B. ; Arbizu, J. ; Langen, K.-J.FZJ*

2017
Elsevier [Amsterdam u.a.]

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/13538  doi:10.1016/j.nicl.2016.12.020

Abstract: Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)
2. Physik der Medizinischen Bildgebung (INM-4)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2017

---

Database coverage:
; ; ; ; Current Contents - Clinical Medicine ; DOAJ Seal ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---